Novel Designs and End Points for Phase II Clinical Trials : Phase II Trials: Designs for the futureADJEI, Alex A; CHRISTIAN, Michaele; IVY, Percy et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1866-1872, issn 1078-0432, 7 p.Article

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international surveyPAOLETTI, Xavier; LE TOURNEAU, Christophe; MASSARD, Christophe et al.European journal of cancer (1990). 2014, Vol 50, Num 12, pp 2050-2056, issn 0959-8049, 7 p.Article

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents ― Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studyPOSTEL-VINAY, Sophie; COLLETTE, Laurence; IVY, Percy et al.European journal of cancer (1990). 2014, Vol 50, Num 12, pp 2040-2049, issn 0959-8049, 10 p.Article

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and TanespimycinVAISHAMPAYAN, Ulka N; BURGER, Angelika M; SAUSVILLE, Edward A et al.Clinical cancer research (Print). 2010, Vol 16, Num 14, pp 3795-3804, issn 1078-0432, 10 p.Article

A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumorsSCHELMAN, William R; MORGAN-MEADOWS, Sherry; IVY, Percy et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 6, pp 1147-1156, issn 0344-5704, 10 p.Article

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal CarcinomaLIM, Wan-Teck; NG, Quan-Sing; TONG SAN KOH et al.Clinical cancer research (Print). 2011, Vol 17, Num 16, pp 5481-5489, issn 1078-0432, 9 p.Article

Phase 1 Study of Oxaliplatin and Irinotecan in Pediatric Patients With Refractory Solid Tumors : A Children's Oncology Group StudyMCGREGOR, Lisa M; SPUNT, Sheri L; FURMAN, Wayne L et al.Cancer. 2009, Vol 115, Num 8, pp 1765-1775, issn 0008-543X, 11 p.Article

Phase 1 Study of an Oxaliplatin and Etoposide Regimen in Pediatric Patients With Recurrent Solid TumorsMCGREGOR, Lisa M; SPUNT, Sheri L; SANTANA, Victor M et al.Cancer. 2009, Vol 115, Num 3, pp 655-664, issn 0008-543X, 10 p.Article

Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive daysDOWLATI, Afshin; HOPPEL, Charles L; INGALLS, Stephen T et al.Journal of clinical oncology. 2001, Vol 19, Num 8, pp 2309-2318, issn 0732-183XArticle

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancerCAO, Carolyn; ALBERT, Jeffrey M; LING GENG et al.Cancer research (Baltimore). 2006, Vol 66, Num 23, pp 11409-11415, issn 0008-5472, 7 p.Article

Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood PerfusionGREGORY SORENSEN, A; EMBLEM, Kyrre E; JAIN, Rakesh K et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 2, pp 402-407, issn 0008-5472, 6 p.Article

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials GroupOZA, Amit M; ELIT, Laurie; MACKAY, Helen J et al.Journal of clinical oncology. 2011, Vol 29, Num 24, pp 3278-3285, issn 0732-183X, 8 p.Article

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine^®) in cancer patientsKOLESAR, Jill; BRUNDAGE, Richard C; POMPLUN, Marcia et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 2, pp 393-400, issn 0344-5704, 8 p.Article

Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting OutcomeWIDEMANN, Brigitte C; BALIS, Frank M; FOX, Elizabeth et al.Journal of clinical oncology. 2010, Vol 28, Num 25, pp 3979-3986, issn 0732-183X, 8 p.Article

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumorsKOLESAR, Jill; WEI HUANG; WILDING, George et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 1, pp 79-86, issn 0344-5704, 8 p.Article

Phase 1 Study of XL119, a Rebeccamycin Analog, in Patients With Refractory Hematologic MalignanciesBORTHAKUR, Gautam; ALVARADO, Yesid; RAVANDI-KASHANI, Farhad et al.Cancer. 2008, Vol 113, Num 2, pp 360-366, issn 0008-543X, 7 p.Article

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function : A national cancer institute organ dysfunction working group studySYNOLD, Timothy W; TAKIMOTO, Chris H; LENZ, Heinz Josef et al.Clinical cancer research. 2007, Vol 13, Num 12, pp 3660-3666, issn 1078-0432, 7 p.Article

Inflammatory breast cancer as a model disease to study tumor angiogenesis : Results of a phase IB trial of combination SU5416 and doxorubicinOVERMOYER, Beth; PINGFU FU; ABDUL-KARIM, Fadi W et al.Clinical cancer research. 2007, Vol 13, Num 19, pp 5862-5868, issn 1078-0432, 7 p.Article

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432LORUSSO, Patricia M; VENKATAKRISHNAN, Karthik; TAKIMOTO, Chris H et al.Clinical cancer research (Print). 2012, Vol 18, Num 10, pp 2954-2963, issn 1078-0432, 10 p.Article

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumorsBRELL, Joanna M; KRISHNAMURTHI, Smitha S; RATH, Linda et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 4, pp 547-553, issn 0344-5704, 7 p.Article

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib MalateGLENN LIU; JERAJ, Robert; MARNOCHA, Rebecca et al.Clinical cancer research (Print). 2011, Vol 17, Num 24, pp 7634-7644, issn 1078-0432, 11 p.Article

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid TumorsRINI, Brian I; GARCIA, Jorge A; TRIOZZI, Pierre et al.Clinical cancer research (Print). 2009, Vol 15, Num 19, pp 6277-6283, issn 1078-0432, 7 p.Article

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionTAKIMOTO, Chris H; GRAHAM, Martin A; SYNOLD, Timothy W et al.Clinical cancer research. 2007, Vol 13, Num 16, pp 4832-4839, issn 1078-0432, 8 p.Article

A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neckCOONEY, Matthew M; TSERNG, Kou-Yi; IVY, Percy et al.Cancer chemotherapy and pharmacology. 2005, Vol 55, Num 3, pp 295-300, issn 0344-5704, 6 p.Article

Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G₂WIDEMANN, Brigitte C; BALIS, Frank M; MOERTEL, Christopher L et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 20, pp 1557-1559, issn 0027-8874, 3 p.Article